Respiratory Syncytial Virus (RSV) Infection

2

Review clinical trials related to Respiratory Syncytial Virus (RSV) Infection. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Assessing the Burden of Respiratory Syncytial Virus (RSV)

This study examines the impact of Respiratory Syncytial Virus (RSV) on people of all ages, from infants to the elderly. It uses hospital records collected between January 2018 and December 2024 to understand: * How often does RSV occur * Who is most at risk * The long-term and financial effects of RSV

Participants needed: 1,500
Trial details
Biological sex: AllType: ObservationalSponsor: Abu Dhabi Health Services CompanyUpdated: Jun 19, 2025Locations: 1
Eligibility criteria

Patients of all ages with a confirmed diagnosis of RSV infection [+2]

Patients with suspected RSV infection that is not laboratory-confirmed [+1]

Status: Recruiting

In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized With Streptococcus Pneumoniae (Spn)

The NoseSpn-Elderly study aims at characterizing the immune response in the upper respiratory tract in adults aged 60 and over diagnosed with a pneumonia due to a Streptococcus pneumoniae (Spn) infection. The immune response during the acute phase of the infection and after recovery will be compared to the immune response of asymptomatic Spn carriers as well as to the immune response of patients diagnosed with a viral respiratory infection (flu or respiratory syncytial virus (RSV)). The primary objective of this observational study is to quantify the inflammatory response in the nasal cavity and to correlate it with bacterial/viral load and with clinical parameters. The study also aims to compare the inflammatory response measured in the nose to that measured in the blood. Participants will have two study visits including a blood draw, several nasal samplings (nasal lining fluid and nasal cells) and a saliva sampling, one within 72 hours of their hospital admission and another one month later. Nasal lining fluid and saliva will be obtained every two or three days until discharge from the hospital or resolution of symptoms. During those visits, questions regarding symptoms will be asked.

Participants needed: 280
Trial details
Age: 60-85Biological sex: AllType: ObservationalSponsor: University Hospital, GenevaUpdated: May 31, 2025Locations: 1
Eligibility criteria

Aged 60-85 years [+6]

Immunosuppression, [+3]